ANG1005 in Patients With Recurrent High-Grade Glioma

NCT01967810 ↗

Phase 2 Completed 73 enrolled Angiochem Inc

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of ANG1005 in patients.

Timeline

Start: 2013-10
Primary completion: 2016-02
Completion: 2017-09

Publications

Dmello C, Brenner A, Piccioni D, Wen PY, Drappatz J, Mrugala M, Lewis LD, Schiff D, Fadul CE, Chamberlain M, Kesari S, Ahluwalia M, Ghosh D, Sonabend AM, Kumthekar P. Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma. Neurooncol Adv. 2024 Dec 14;6(1):vdae186. doi: 10.1093/noajnl/vdae186. eCollection 2024 Jan-Dec.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ANG1005	Peptide	600 mg/m2	Intravenous
Subject	ANG1005	Peptide	650 mg/m2	Intravenous
Background	Bevacizumab	Monoclonal antibody	—	—

ANG1005 in Patients With Recurrent High-Grade Glioma

Summary

Timeline

Publications

Drugs

Indications